Abivax SA Sustainability Reports

Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response. The company primarily targets chronic inflammatory diseases, with its lead drug candidate in Phase 3 clinical trials for ulcerative colitis.

Sector: Professional & technical services

Country: France

Exchange: Euronext Paris

LEI: 969500D8TMNB184OJU95

FIGI: BBG009CG7F82

7 reports from 2015 to 2025

• Abivax SA 2025 Universal Registration Document
• Abivax SA 2023 Universal Registration Document
• Abivax SA 2020 Universal Registration Document
• Abivax SA 2018 Registration Document
• Abivax SA 2017 Registration Document